info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Obstructive Lung Disease Companies

Obstructive lung disease companies focus on developing medical solutions for conditions characterized by airflow limitation, such as chronic obstructive pulmonary disease (COPD) and asthma. These companies contribute to pulmonology by providing medications, inhalers, and therapies to manage and improve respiratory function in individuals with obstructive lung diseases.

Obstructive Lung Disease Key Companies

 

Latest Obstructive Lung Disease Companies Update


AstraZeneca Received FDA approval for their triple-therapy inhaler, Breztri Aerosolizer, for treating moderate-to-severe COPD patients, offering a convenient one-inhaler option for symptom control.Partnered with AI companies to develop algorithms for analyzing respiratory data and predicting exacerbations in COPD patients, enabling proactive interventions.


GlaxoSmithKline (GSK) Launched their next-generation inhaler, Trelegy Ellipta, in new markets for COPD treatment, offering a once-daily single inhaler option for improved adherence.Conducted clinical trials on their investigational inhaled corticosteroid/long-acting beta-agonist combination therapy for asthma, targeting specific inflammatory pathways for potentially improved symptom control.


Novartis Presented positive Phase III data for their inhaled IL-17 inhibitor, QMF149, for treating severe asthma, showcasing its potential to control inflammation and reduce exacerbations.Expanded their research efforts on gene therapy approaches for lung diseases like alpha-1 antitrypsin deficiency, a rare genetic form of COPD, aiming for curative solutions.


Teva Pharmaceuticals Unveiled their new digital inhaler platform, Digihalerâ„¢, with integrated sensors and a companion app, providing data on medication usage and allowing for personalized dose adjustments.Collaborated with patient advocacy groups to develop educational resources and support programs for individuals living with OLD, empowering them to manage their condition effectively.


Lung Foundation of India Launched a nationwide awareness campaign on COPD, emphasizing early diagnosis, risk factors, and treatment options, aiming to reach underserved communities.Provided funding for research initiatives investigating the prevalence and impact of OLD in India, guiding public health strategies and resource allocation.


List of Obstructive Lung Disease Key Companies in the Market



  • GlaxoSmithKline (GSK) (U.K)

  • Novartis AG (Switzerland)

  • Merck & Co. Inc. (U.S)

  • Abbott Laboratories (U.S)

  • Boehringer Ingelheim (Germany)

  • AstraZeneca (U.K)

  • Roche Holding AG (Switzerland)

  • Teva Pharmaceutical Industries (Israel)

  • Vectura Group (U.K)

  • Pfizer Inc. (U.S)

  • Mylan (U.S.)

  • Aerovance Inc. (U.S.)

  • Alkermes Inc. (U.S.)

  • Almirall SA. (U.S.)

  • Genentech Inc. (U.S.)

  • Sepracor, Inc. (U.S.)

  • Skyepharma plc (U.S.)


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.